Cedars-sinai medical center and aikido pharma inc. to codevelop novel immuno-oncology cancer treatment

New york, march 11, 2022 /prnewswire/ -- aikido pharma inc. (nasdaq: aiki) ("aikido" or the "company") today announced that the company and cedars-sinai medical center have agreed under their master collaboration agreement to co-fund and codevelop a novel immuno-oncology treatment designed to promote the destruction of cancer cells by a patient's own "killer" t-cells. the company and cedars-sinai will share costs, expenses and management of the drug co-development and will leverage the talent of cedars-sinai technology ventures and the lead scientists who originated the novel treatment.
DOMH Ratings Summary
DOMH Quant Ranking